Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
65 results about "Solid-Phase Synthesis Techniques" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Techniques used to synthesize chemicals using molecular substrates that are bound to a solid surface. Typically a series of reactions are conducted on the bound substrate that results in either the covalent attachment of specific moieties or the modification of existing function groups. These techniques offer an advantage to those involving solution reactions in that the substrate compound does not have to be isolated and purified between the reaction steps.
Methods and compositions for producing biopolymeric arrays
Methods and compositions are provided for producing arrays of polymeric binding agents. In the subject methods, the individual polymers of the array are synthesized using solid phase synthesis techniques on the surface of a substrate. A critical feature of the invention is that one or more locations on the substrate surface are spatially and temporally protected by a protective bubble during the synthesis protocol, where the protective bubble may be produced using any convenient bubble producing means. The bubble producing means may be a component of either a substrate or a structure separate from the substrate. Also provided are the arrays produced by the subject methods, kits for use in practicing the subject methods, and methods of using the arrays in analyte detection assays, including hybridization assays, such as gene discovery, differential gene expression and gene sequencing assays.
Owner:AGILENT TECH INC
Solid phase methods for polynucleotide production
Polynucleotides having in excess of 1,000 nucleotides can be prepared using a solid phase synthesis technique. A feature of the technique is the use of a reusable solid support that contains covalently bound oligonucleotide. This covalently bound oligonucleotide is annealed to a bridge oligonucleotide, where the bridge is also annealed to a first oligonucleotide that forms a portion of the target polynucleotide. After the target polynucleotide is synthesized, it can be removed from the solid support under denaturing conditions, and the solid support re-used to prepare additional target polynucleotides. The yield of the target polynucleotide increases when shearing force is applied to the solid support that is linked to the growing oligonucleotide. This shearing force is thought to extend the growing end of the oligonucleotide away from contact with other oligonucleotide bound to the solid support and make that end more accessible to annealing with solution oligonucleotide. The synthesis is conveniently accomplished on a porous frit, where reagents and washing solutions are pumped through the frit.
Owner:BLUE HERON BIOTECH
Solid phase methods for polynucleotide production
InactiveUS20050106606A1Improve responseMore cost-effectivelySequential/parallel process reactionsSugar derivativesFritCombinatorial chemistry
Polynucleotides having in excess of 1,000 nucleotides can be prepared using a solid phase synthesis technique. A feature of the technique is the use of a reusable solid support that contains covalently bound oligonucleotide. This covalently bound oligonucleotide is annealed to a bridge oligonucleotide, where the bridge is also annealed to a first oligonucleotide that forms a portion of the target polynucleotide. After the target polynucleotide is synthesized, it can be removed from the solid support under denaturing conditions, and the solid support re-used to prepare additional target polynucleotides. The yield of the target polynucleotide increases when shearing force is applied to the solid support that is linked to the growing oligonucleotide. This shearing force is thought to extend the growing end of the oligonucleotide away from contact with other oligonucleotide bound to the solid support and make that end more accessible to annealing with solution oligonucleotide. The synthesis is conveniently accomplished on a porous frit, where reagents and washing solutions are pumped through the frit.
Owner:BLUE HERON BIOTECH
Solid phase synthetic technique for thymosin alpha1
ActiveCN101104638AAdvantages of solid phase synthesis processEasy to purifyThymopoietinsPeptide preparation methodsFluoroacetic acidAcetic anhydride
The invention relates to a solid-phase synthesis process of a thymosin alpha 1, belonging to the polypeptide solid-phase synthesis technical field. The invention comprises the following steps: a. a Fmoc-Rink Amide AM resin or a Fmoc-Rink Amide MBHA resin is used as carrier, an H2N-Rink Amide AM resin or an H2N-Rink Amide MBHA resin is obtained after deprotection of the Fmoc; b. side chain carboxyl group of Fmoc-Asp-X is connected with resin amino by the method of solid-phase synthesis to obtain the Fmoc-Asp (resin)-X; c. the left amino acid in the sequence is synthesized in solid-phase with the Fmoc strategy; d. after the amino protection group Fmoc of N terminal amino acid is removed, the N terminal amino acid is acetylated by acetic anhydride and pyridine; e. then the acetylated N terminal amino acid is cut by a cracking agent (tri fluoroacetic acid / benzoylate sulfide / 1, 2- dithioglycol / Anisole) to obtain the thymosin alpha 1; f. crude product of the thymosin alpha 1 is prepared and separated by HPLC to obtain the pure thymosin alpha 1. The invention can increase significantly the yield of the thymosin alpha 1 and decrease the production cost, which is helpful for scale production and has better industrialization prospect.
Owner:苏州天马医药集团天吉生物制药有限公司
Low-temperature sintered ternary system relaxor ferroelectric ceramic material, preparation method and application of low-temperature sintered ternary system relaxor ferroelectric ceramic material
ActiveCN105084898AHigh curie temperatureImproved high-field piezoelectric performanceCeramic sinteringMetallurgy
The invention relates to a low-temperature sintered ternary system relaxor ferroelectric ceramic material, a preparation method and application of the low-temperature sintered ternary system relaxor ferroelectric ceramic material. The problems that existing PIN-PMN-PT ceramic sintering temperature is high, environmental pollution is caused by severe lead volatilization, the material performance is reduced, and the production cost is high are solved. The chemical general formula of the ceramic material is xPb(In1 / 2Nb1 / 2)O3-(1-x-y)Pb(Mg1 / 3Nb2 / 3)O3-yPbTiO3-awt.%CuO. The method includes the steps of firstly, conducting a solid-phase reaction to synthesize a precursor of MgNb2O6; secondly, conducting a solid-phase reaction to synthesize a precursor of InNbO4; thirdly, conducting a solid-phase reaction to synthesize matrix powder of PIN-PMN-PT; fourthly, preparing low-temperature sintered ternary system relaxor ferroelectric ceramic through the combination of the solid-phase synthesis technology and the curtain coating lamination process. The low-temperature sintered ternary system relaxor ferroelectric ceramic material, the preparation method and the application are used for preparing high-power piezoelectric buzzers and multi-layer piezoelectric devices.
Owner:HARBIN INST OF TECH
Phosphorodiamidate morpholino oligomer synthetized by solid phase and method thereof
The invention relates to a method for synthetizing phosphorodiamidate morpholino oligomer by solid phase. A cheap resin is utilized; Wang resin is as a solid phase carrier; the phosphorodiamidate morpholino oligomer (PMO) structure of which terminal hydroxyl is protected by tert-butyl dimethyl silicon is shown in the description, wherein a structure of basic group B is any one of adenine (A), guanine (G), cytosine (C) and thymine (T). Compared with the existing solid phase synthetic technology, the method provided by the invention can greatly reduce synthetic cost, and can be suitable for mass production of phosphorodiamidate morpholino oligomer.
Owner:天津特安化学科技有限公司
Solid phase synthesis method of leuprorelin
InactiveCN101407540AAvoid the process of alkaline aminolysisHigh yieldPeptide preparation methodsBulk chemical productionLeuprorelinFreeze-drying
The invention relates to a solid phase synthesis method of leuprorelin, which uses 4-((1-N-Alkylamino)ethyl) phenoxy-butyramide resin as a solid phase carrier to carry out procedure reaction, and peptide whole protecting resin can be obtained by sequentially carrying out condensation reaction to connect protecting amino-acid; crude peptide can be obtained by cutting the resin by trifluoroacetic acid, and the crude peptide is dissolved in an acetic acid water solution of 5 percent, and the leuprorelin can be obtained by purifying, leaching, condensing and freeze drying the opposite phase high performance liquid chromatograph columns of C18 fillers. The invention uses a novel solid phase resin, and products decorated by peptide chain carbon end alkyl can be obtained directly after finishing assembling the peptide chain by the solid phase synthesis technology and using acid hydrolysis to cut the peptide from the resin after, and the solid phase synthesis method of the leuprorelin is convenient in operation, reduces synthesis steps for synthesizing the leuprorelin greatly and improves the yield.
Owner:ADLAI NORTYE BIOPHARMA CO LTD
Nucleic acid-drug conjugate, drug delivery system, preparation method and application thereof
ActiveCN109568595AMeet biocompatibilityLow immunogenicityOrganic active ingredientsSugar derivativesDrug conjugationNucleotide
The invention belongs to the field of biological medicine and specifically discloses a nucleic acid-drug conjugate based on phosphorothioate modified nucleic acid, a drug delivery system and a preparation method thereof. Phosphorothioate groups in the phosphorothioate modified nucleic acid react with groups modified on drug molecules and capable of generating electrophilic reaction with the phosphorothioate groups, so as to form the nucleic acid-drug conjugate; the nucleic acid-drug conjugate can be self-assembled into drug-containing nano-carriers in various forms for drug delivery, in the manner of selecting different nucleotide sequences including functional nucleic acid; compared with the prior art, the invention has the advantages that the nucleic acid-drug conjugate can be acquired through a simple solid-phase synthesis technology, grafting sites and assembling forms of drug molecules on nucleic acid skeleton can be accurately controlled and the method has universality to chemotherapeutic drugs; according to the nucleic acid-drug conjugate, the drug delivery system, the preparation method and the application thereof disclosed by the invention, physicochemical properties and in vivo distribution properties of chemotherapeutic drugs are obviously improved, therapeutic effect thereof can be promoted and combination therapy of gene therapy and chemotherapy can be realized.
Owner:SHANGHAI JIAO TONG UNIV
Preparation method of piece-shaped tungsten disulfide nanometer lubricating oil additive
The invention relates to manufacture of lubricating oil, in particular to a preparation method of a-piece shaped tungsten disulfide nanometer lubricating oil additive. The preparation method comprises the steps as follows: weighing raw materials which are respectively the tungsten powder and sulfur powder based on the mol ratio of the tungsten to the sulfur of 1: 2.5 to 1: 3; mixing the tungsten powder and the sulfur powder through ball milling, and then adding the mixture to a reaction kettle; transferring the reaction kettle under a protective atmosphere of 600 to 800 DEG C, and annealing for 0.5 to 2 hours at constant temperature; and then naturally cooling to reach the room temperature, so as to obtain the piece-shaped WS2 nanometer lubricating oil additive. According to the preparation method of the piece-shaped tungsten disulfide nanometer lubricating oil additive provided by the invention, a solid phase synthesis technology is applied to synthesizing an inorganic micro-nanometer material; the preparation method has the advantages of being simple in technology, simple and convenient to operate, controllable in temperature, and short in response time; and the preparation method is low in cost, and is suitable for large-scale industrial production; and compared with traditional preparation method, the tungsten powder is adopted to replace the tungsten oxide, thus higher purity of WS2 is achieved, as well as nice appearance; and moreover, higher specific surface area and the tribological properties can be obtained.
Owner:ZHENJIANG COLLEGE
Polydextrose with controllable molecular weight and rapid preparation method thereof
ActiveCN103766695AHigh purityHigh efficacy component contentFood preparationPolydextroseHydroxymethylfurfural
The invention relates to an edible dietary fiber and a rapid preparation method thereof, and in particular relates to a polydextrose with a controllable molecular weight and the rapid preparation method thereof. The polydextrose is characterized in that the average molecular weight of the polydextrose ranges from 600Da to 3500Da; the average polymerization degree of the polydextrose ranges from 4 to 20; the content of the polydextrose is greater than or equal to 99.5%; and glucose and 5-hydroxymethylfurfural are not contained in the polydextrose. The invention further discloses the rapid preparation method of the polydextrose. The method comprises the following steps: performing microwave radiation on a mixture of the glucose and sorbitol for 0.5 to 8 minutes by taking deionized water as a reaction initiator and an edible acid as a reaction catalyst under the condition of the microwave radiation so as to obtain a polydextrose product; smashing the polydextrose product; and then washing the polydextrose product with ethyl alcohol and drying, thereby obtaining the polydextrose without containing the glucose, the 5-hydroxymethylfurfural and the edible acid. The polydextrose which is prepared by adopting a microwave-assisted solid-phase synthesis technology has the characteristics of being rapid in reaction speed, high in synthesis yield, low in production cost, environment-friendly, controllable in molecular weight, neutral in pH (Power Of Hydrogen) and milk white.
Owner:JIANGNAN UNIV
Method for synthesizing mono pegylation-thymopentin by solid phase and liquid phase combination
ActiveCN101870732APrecise structureEasy to operateCarrier-bound/immobilised peptidesSide chainMass spectrometry
The invention relates to a method for synthesizing mono pegylation-thymopentin (mPEG-TP5) by solid phase and liquid phase combination. The method comprises the following steps of: connecting modified polyethylene glycol (mPEG-SCM) to side chain amino of lysine protected by amino by adopting liquid-phase synthesis technology; synthesizing mPEG-TP5 by adopting solid-phase synthesis technology; analyzing and purifying high-efficiency liquid phase through dialysis; and identifying the product structure through nuclear magnetism and mass spectrum. The mono pegylation-thymopentin synthesized by themethod improves the defect that the conventional parent medicament thymopentin has quick biodegradation, poor digesting stability, short biological half-life and the like, and has good application prospect.
Owner:LANZHOU UNIVERSITY
Solid phase synthesis method by gas stream to increase efficiency and continuous microwave radiation, and apparatus therefor
ActiveCN1663674AHigh activityIncrease average energyEnergy based chemical/physical/physico-chemical processesStrong acidsProduct gas
The invention is solidoid composition reaction of airflow potentiating continuous microwave radiation and the equipment. It relates to microwave radiation solidoid composition technology field. The method is: in the microwave energy field, the reacting materials are radiated continuously by the microwave on the deferent strip, the jet vertical airflow potentiates through deferent web to solidoid compose the reacting materials. The equipment comprises a reacting chamber with a plurality of microwave resources, a deferent strip carrying the reacting material and moving horizontally, the airflow deferent strip web in the reacting chamber to implement vertical potentiating and continuous microwave radiation soldoid composition reaction, the exhausting mouth recycling the gas. The equipment can make the microwave radiate the materials evenly, prevents the coking reaction caused by side-product strong acid and partial heat accumulation, lowers the cost, increases the reaction speed and improves the purity of products and composition efficiency of microwave.
Owner:JIANGNAN UNIV
Preparation method for lanreotide
InactiveCN104497130AHigh purityHigh yieldSomatostatinsPeptide preparation methodsDipeptideSide chain
The invention relates to the field of polypeptides and particularly relates to a preparation method for lanreotide. The preparation method comprises the following steps: a step I: obtaining a dipeptide segment with an amino acid sequence as shown in SEQ ID No.1; a step II: obtaining hexapeptide peptide resin, wherein the amino acid sequence of the hexapeptide is as shown in SEQ ID No.2; a step III: condensing the dipeptide segment and the hexapeptide peptide resin according to the amino acid sequence of the lanreotide to obtain lanreotide peptide resin; and a step IV: cracking the lanreotide peptide resin to remove resin and a side chain protective group, thereby obtaining a lanreotide crude product, and then refining the lanreotide crude product to obtain lanreotide. The invention provides a method for combining solid-phase synthesis with liquid-phase synthesis. A 2+6 segment solid-phase synthesis technology is adopted to greatly improve the purity of the crude product, so that the yield of the final product is increased, and the preparation cost is lowered.
Owner:浙江华军药业有限公司
Solid-phase synthesis process of angiotensinamide as well as intermediate and application thereof
ActiveCN103374058AHigh purityHigh yieldPeptide/protein ingredientsPeptide preparation methodsChemical structureSide chain
The invention discloses a process for producing angiotensinamide with a chemical structure of H-Asn-Arg-Val-Tyr-Val-His-Pro-Phe-OH by adopting solid-phase synthesis technology and an intermediate adopted in the method. The method comprises the following steps of: (a) preparing protected angiotensinamide with a chemical structure of R1-Asn-Arg(R2)-Val-Tyr(R3)-Val-His(R4)-Pro-Phe-R5, wherein R1 is an amino protecting group, R2, R3 and R4 are side chain protecting groups, and R5 is carboxyl resin; and (b) under the action of a cutting reagent, deprotecting and separating the protected angiotensinamide obtained in the step (a) from the resin to generate angiotensinamide with the chemical structure of H-Asn-Arg-Val-Tyr-Val-His-Pro-Phe-OH. The method for synthesizing angiotensinamide is environment-friendly and efficient, has low requirements for equipment, and can be applied to large-scale industrial production.
Owner:SPH NO 1 BIOCHEM & PHARMA CO LTD
Process for the Synthesis of Cyclic Heptapeptide
The present invention relates to an improved process for the large scale synthesis of cyclic heptapeptide using Fmoc solid phase synthesis technique. The described process assembles the peptide on a solid support resin by coupling to one another by peptide bonds to obtain a peptide wherein the coupling of cysteine to the resin employs a combination of solvents to reduce cysteine racemization. The process described relates to the use of C1-C4 alcohols as total substitute to organic nitriles thus making the process cost effective, non-toxic and eco-friendly.
Owner:USV LTD
Preparation method for carbetocin
ActiveCN106478779AHigh yieldEasy to sampleOxytocins/vasopressinsPeptide preparation methodsFreeze-dryingCarbetocin
The invention discloses a preparation method for carbetocin. The preparation method comprises the following steps: subjecting swelled, deprotected and washed amino resin to reacting with an activated protected amino acid solution in a constant-temperature vibrator, carrying out successive introduction into protected amino acids corresponding to first-to-eighth amino acids accounting from the resin and into butyric acid at the tail end of N; subjecting prepared carbetocin precursor peptide 1-amino resin to deprotection, carrying out washing, then carrying out drying until the dried carbetocin precursor peptide 1-amino resin is of a granular shape, adding a cutting reagent, and carrying out a cutting reaction and settling; dissolving a carbetocin precursor peptide II in a solvent, removing impurities by adopting a reversed phase highly-efficient liquid chromatography method, and carrying out liquid-phase cyclizing so as to obtain a crude carbetocin peptide III; and subjecting the crude carbetocin peptide III to purifying and freeze-drying so as to obtain a pure carbetocin polypeptide. The preparation method provided by the invention utilizes an Fmoc solid-phase synthetic principle to develop a solid-phase synthetic technology; and through process optimization, the yield of crude carbetocin is up to 90% or above, so the yield of carbetocin is greatly improved.
Owner:合肥国肽生物科技有限公司
Foldable polymers as probes
Disclosed herein are novel probes, which can be used to detect and identify target molecules of interest in a sample. The disclosed probes can be used to monitor conformational changes induced by molecular recognition events in addition to providing signaling the presence and / or identity of a target molecule. Methods, including solid phase synthesis techniques, for making probe molecules that exhibit changes in their optical properties upon target molecule binding are described in the disclosure. Also disclosed herein are novel chromophore moieties, which have tailored fluorescent emission spectra.
Owner:WASHINGTON STATE UNIV RES FOUND INC
Solid phase synthesis technique for melanotan-II
ActiveCN101195654AEasy to synthesizeSave raw materialsPeptide preparation methodsMelanotan IISynthesis methods
The invention relates to a synthesis method of melanotan-II, in particular to a solid-phase synthesis method of melanotan-II, which can resolve the problems of prior art which is hard to synthesize annular polypeptide and hard to remove protection. The invention forms ring on resin directly with simple reaction. The technical scheme of the invention comprises using Fmoc-Linker Amide AM Resin as carrier, connecting amino acids in turn accoriding to Fmoc / tBu solid polypeptide synthesis method, acetylizing, hydrolyzing NaOH solution and dioxane to remove trifluoroacetyl group and methyl ester on amino acids, using condenser to directly form ring on resin, and using the mixture of trifluroacetic acid, water, benzoylate sulfide and disulfide ethanol to cut off peptide from resin, to obtain crude melanotan-II, preparing HPLC purified transgenic acetate, freezing and drying to obtain acetate melanotan-II. The invention provides a method for simply synthesizing large-scale acetate melanotan-II.
Owner:上海吉尔多肽有限公司
Cell-penetrating peptide and application thereof
ActiveCN109608519AEfficient Mediated DeliveryNon-immunogenicOrganic active ingredientsPeptidesImmunogenicityAmino acid
The invention provides a cell-penetrating peptide. The cell-penetrating peptide has an amino acid sequence as follows: Arg-Arg-Lys-Lys-Trp-Trp. The cell-penetrating peptide is capable of mediating delivery of doxorubicin into cells. The cell-penetrating peptide provided by the invention is non-toxic and non-immunogenic. Moreover, the solid-phase synthesis technology of polypeptides is mature, cheap, easy to obtain and conducive to quality control.
Owner:NANYANG NORMAL UNIV
Thrombin-inhibited polypeptide and preparation method and application thereof
The invention relates to the field of medicine, in particular to a polypeptide compound for preventing and treating, or preventing atherosclerosis. Thrombin-inhibited polypeptide 2 is characterized by comprising the sequence of RGDLFRKSADGFIALMKLKK, is prepared by adopting the Fmoc protective solid phase synthesis technology, and can be connected with an adjuvant in a covalence manner, wherein the adjuvant is bovine serum albumin, human serum albumin or polyethylene glycol; the thrombin-inhibited polypeptide 2 can be applied in treating atherosclerosis related diseases; the atherosclerosis related diseases comprise angina pectoris, myocardial infarction, arrhythmia, stroke, encephalanalosis, intractable hypertension, renal insufficiency and other diseases; the atherosclerosis related diseases can be treated in various methods of administration, including subcutaneous or intramuscular injection, intravenous injection or intravenous drip, oral medication, such as pills and capsules, nasal spray and the like. The thrombin-inhibited polypeptide 2 can inhibit the thrombin in a targeted manner, inhibits blood coagulation, and achieves the function of preventing or treating atherosclerosis.
Owner:BEOGENE BIOTECH GUANGZHOU
Dendritic cell (DC)-based hepatitis B virus T epitope peptide
The invention relates to the fields of protein engineering, gene engineering and biomedicines, in particular to a dendritic cell (DC)-based hepatitis B virus T epitope peptide. The technical scheme is that: the DC-based hepatitis B virus T epitope peptide is characterized by consisting of nine amino acid residues in the amino acid sequence of QLFHLCLII. The basic amino acid is taken as a framework, same preset amino acid sequences are simultaneously synthesized on the framework by a solid-phase synthesis technology, a hepatitis B virus is taken as a design target, and the DC-based hepatitis B virus specific epitope peptide is produced by the synthesis technology; the DC is loaded with the epitope peptide in vitro, and the mature DC is injected into bodies of a specific group to specifically generate effects of removing in-vive virus and improving clinical symptoms aiming at hepatitis B virus infection, particularly chronic hepatitis.
Owner:江苏安泰生物技术有限公司
Recombinant human-derived antimicrobial peptide C16LL-37 and application method thereof in streptococcus mutans bioactivity role
InactiveCN106008718AReduce sensitivitySignificant target specificityAntibacterial agentsPeptide/protein ingredientsAntimikrobielle peptideChemical synthesis
The invention relates to the technical field of biological engineering, relates to a recombinant human-derived antimicrobial peptide C16LL-37 and an application method thereof in streptococcus mutans bioactivity role, and analysis application of antimicrobial activity, targeting property, hemolytic property and other bioactivities of the recombinant antimicrobial peptide C16LL-37. A standard solid-phase synthesis technique is adopted for synthesis, an amino acid sequence of a human-derived antimicrobial peptide LL-37 is connected with 16 amino acid sequences CSPC16 of a C end of streptococcus mutans CSP through connecting body-GGG-connection, and the recombinant human-derived antimicrobial peptide C16LL-37 having specific targeting ability is synthesized. In conclusion, with research and development of the human-derived specifically targeted antimicrobial peptide C16LL-37, not only are the problems that natural antimicrobial peptides have broad antimicrobial spectra, easy generation of drug resistance, low biological efficiency, high difficulty of screening and the like solved, but also the shortcomings that chemically synthesized antimicrobial peptides have low chemical combination efficiency and fusion proteins are unstable are overcome. In addition, an AMP region of the C16LL-37 is derived from a human body, so the C16LL-37 has relatively high biological safety and lays a firm foundation for wide application in clinic in future.
Owner:NORTHWEST UNIVERSITY FOR NATIONALITIES
Process for the synthesis of cyclic heptapeptide
The present invention relates to an improved process for the large scale synthesis of cyclic heptapeptide using Fmoc solid phase synthesis technique. The described process assembles the peptide on a solid support resin by coupling to one another by peptide bonds to obtain a peptide wherein the coupling of cysteine to the resin employs a combination of solvents to reduce cysteine racemization. The process described relates to the use of C1-C4 alcohols as total substitute to organic nitriles thus making the process cost effective, non-toxic and eco-friendly.
Owner:USV LTD
DC cell-based hepatitis B virus T epitope peptide
InactiveCN104387447AImprove clinical symptomsDigestive systemAntiviralsAcute hepatitis BProtein engineering
The invention relates to the field of protein engineering, gene engineering and biomedicine, and particularly relates to a DC cell-based hepatitis B virus T epitope peptide. According to the technical scheme, the DC cell-based hepatitis B virus T epitope peptide is characterized by consisting of 9 amino acid residues with an amino acid sequence of QLFHLCLII. According to the DC cell-based hepatitis B virus T epitope peptide, basic amino acid is used as a framework, a solid-phase synthesis technology is adopted, a same preset amino acid sequence is simultaneously synthesized on the framework; with the hepatitis B virus as a design target, and the DC cell-based hepatitis B virus specific epitope peptide is produced by adopting a synthesis technology; the epitope peptide is loaded in-vitro on the DC cell, the mature DC cell is infused into bodies of specific people, and generation of the specificity is capable of eliminating the hurt caused by hepatitis B virus infection and particularly cleaning viruses in the body and improving the clinical syndromes against acute hepatitis B.
Owner:阎平希 +1
Dimer polypeptide with antibacterial and immunomodulating dual functions and application thereof
InactiveCN110066317AHas antibacterial propertiesFunctionalAntibacterial agentsPeptide/protein ingredientsSide chainCytokine
The invention discloses a dimer polypeptide with antibacterial and immunomodulating dual functions and application thereof, and belongs to the field of biomedicine. The polypeptide is obtained by thesteps that two stage are divided for preparation by means of a conventional polypeptide solid-phase synthesis technique, then a disulfide bond is formed by thiol pairing of cysteine side chains, and finally semi-preparative reverse high performance liquid chromatography is adopted for purification. Pharmacological experimental results show that the polypeptide has a good inhibition effect on Gram-positive bacteria; the expression of proinflammatory cytokines TNF-alpha, IL-1beta, IL-6 and IL-17 in murine macrophages RAW264.7 induced by lipopolysaccharide can also be inhibited, and the expression of an anti-inflammatory cytokine IL-10 is promoted. Meanwhile, the bifunctional polypeptide shows low hemolytic activity, the artificial preparation is convenient, the pharmacological activity is definite, and the polypeptide has further development value and industrialization potential.
Owner:WUHAN UNIV
Insulin amyloid polypeptide inhibitor, preparation method and application thereof
The invention relates to the field of drugs and particularly relates to an inhibitor 1 compound which can treat diabetes. A sequence of the inhibitor 1 is KATPIESHQVJAAEKRKC. A preparation method of the inhibitor 1 is carried out through Fmoc-protected solid-phase synthetic technology, with Rink amide MBHA resin and Fmoc-Gly-Wang resin as supporters, with 6-chloro-1-hydroxylbenzotriazole and N,N-diisopropyl carbodiimide as condensing agents, and with trifluoroacetic acid as a cutting reagent. The invention also provides an application of the inhibitor 1 for preventing or treating diabetes and complications thereof, wherein the complications comprise diabetic nephropathy, diabetic hypertension, diabetic eye diseases and diabetic neurogenic lesion. The inhibitor 1 can be employed for preventing or treating the diabetes and the complications thereof through various dosing methods, such as subcutaneous injection or intramuscular injection, intravenous injection or intravenous drip, and oral medication, such as pills, capsules, nasal spray agent and the like. The islet amyloid polypeptide inhibitor 1 can targetedly inhibit generation of islet amyloid polypeptide, thereby preventing or treating diabetes.
Owner:SUZHOU PULUODA BIOLOGICAL SCI & TECH
Solid phase synthetic technique for thymosin alpha1
ActiveCN101104638BEasy to purifyHigh purityThymopoietinsPeptide preparation methodsAcetic anhydrideFluoroacetic acid
Owner:苏州天马医药集团天吉生物制药有限公司
Preparation of pancreatic cancer associated polypeptide DAP44 monoclonal antibody and application thereof
ActiveCN105017403AHigh affinityImprove featuresImmunoglobulins against animals/humansAnimals/human peptidesAntigenHybridoma technology
The invention analyzes and sieves pancreatic cancer associated polypeptide DTNBP1 Associated Peptide 44 (DAP44) through chromatography high-efficiency separation and mass spectrum proteomics, and discloses an amino acid sequence thereof, and a DAP44 antigen is synthesized by utilizing a polypeptide solid-phase synthesis technology. The DAP44 antigen is taken as an immunogen, monoclonal antibodies for the antigen are prepared by utilizing a hybrid tumor technology, two high-appetency monoclonal antibodies are determined through antibody valence detection, cross pairing and identification of subclass, the antibodies are used for immunohistochemical detection of DAP44, and a foundation is laid for subsequently establishing a DTNBP1 detection kit.
Owner:陈勇
Anticancer peptide containing poly-L-histidine as well as preparation and application thereof
PendingCN106749522ASimple structureNo side effectsPeptide/protein ingredientsPeptide preparation methodsCytotoxicityTherapeutic effect
The invention discloses an anticancer peptide containing poly-L-histidine as well as preparation and application thereof and belongs to the technical field of development and application of antitumor drugs. An amino acid sequence of the poly-L-histidine comprises a plurality of histidines; the poly-L-histidine has efficient antitumor activity. Through the adoption of a polypeptide solid phase synthesis technique, a series of peptides which are rich in histidine and have membrane cracking activity and antitumor activity are built; the peptides have effects of killing cancer cells and is especially capable of killing ovarian cancer SKOV-3 cells under the acid condition with high selectivity; cytotoxicity experiments of in-vitro ovarian cancer SKOV-3 cells, lung cancer A549 cells and breast cancer MCF-7 cells and the tumor-inhibiting experiment of mouse in-vivo ovarian cancer SKOV-3 tumor show that the poly-L-histidine peptide has excellent effects of treating ovarian cancer, lung cancer and breast cancer.
Owner:EAST CHINA UNIV OF SCI & TECH
Insulin amyloid polypeptide inhibitor, preparation method and application thereof
Insulin amyloid polypeptide inhibitor, preparation method and application thereof. The invention relates to the field of drugs and particularly relates to an inhibitor 1 compound which can treat diabetes. A sequence of the inhibitor 2 is VLSVAALNHLDKATPIESH. A preparation method of the inhibitor 2 is carried out through Fmoc-protected solid-phase synthetic technology, with Rink amide MBHA resin and Fmoc-Gly-Wang resin as supporters, with 6-chloro-1-hydroxylbenzotriazole and N,N-diisopropyl carbodiimide as condensing agents, and with trifluoroacetic acid as a cutting reagent. The invention also provides an application of the inhibitor 2 for preventing or treating diabetes and complications thereof, wherein the complications comprise diabetic nephropathy, diabetic hypertension, diabetic eye diseases and diabetic neurogenic lesion. The inhibitor 2 can be employed for preventing or treating the diabetes and the complications thereof through various dosing methods, such as subcutaneous injection or intramuscular injection, intravenous injection or intravenous drip, and oral medication, such as pills, capsules, nasal spray agents and the like. The islet amyloid polypeptide inhibitor 2 can targetedly inhibit generation of islet amyloid polypeptide, thereby preventing or treating diabetes.
Owner:刘旭
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com